Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused on late-stage Parkinsons disease (PD), today announced a strategic global co-development agreement for Infudopa SubC — a next-generation, wearable drug-device therapy that offers a user-friendly, flexible, and physiologically sound alternative to existing advanced Parkinsons treatments, hence empowering patients with greater independence.
This agreement marks a pivotal milestone for Neuraxpharm as it enters the drug-device space with its first-ever combination therapy, reinforcing its commitment to pioneering innovation in CNS and addressing some of the most pressing unmet needs in neurological care.
A New Era in Advanced Parkinsons Treatment
Infudopa SubC is a ready-to-use levodopa-carbidopa solution delivered via a wearable subcutaneous infusion belt pump. It is designed to provide continuous, precise drug delivery for patients with advanced PD who experience motor fluctuations that are no longer adequately managed by oral medications.
Addressing a Growing Global Challenge
PD is the fastest-growing neurological condition worldwide, currently affecting over 10 million people. Global prevalence is expected to double to 20 million by 2050.1,2 For many patients, oral medication loses effectiveness as the disease advances, leaving patients facing disabling motor fluctuations that are better treated by device-aided therapies like Infudopa SubC. Neuraxpharm’s collaboration with Dizlin is a transformative advancement for PD patients, ensuring access to a therapy that is not only effective but also practical and empowering.
Under the terms of this agreement, Neuraxpharm will actively participate in the co-development of the product to ensure its global availability and will receive global exclusive commercialisation rights for Infudopa SubC in Europe, countries outside Europe where it has a direct presence, and via partners in other territories, such as US or Japan, to be agreed by both parties.
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, stated: “Our partnership with Dizlin is a powerful step towards reshaping the future of Parkinsons care. Infudopa SubC is more than a therapy — it’s a life-changing solution, effectively and practically delivering treatment to PD patients. This collaboration reflects our unwavering mission to bring forward differentiated, breakthrough solutions for people living with CNS disorders.”
Björn Velin, CEO of Dizlin Pharmaceuticals, added: “Dizlin Pharmaceuticals is very pleased to have entered into an agreement with a well-established and highly reputable pharmaceutical company specialising in the central nervous system – specifically Parkinsons disease – and with a strong commercial organisation.
“We are committed to bringing our products to market quickly – and confident of being successful in this regard – so that more patients in the advanced stage of Parkinsons disease can gain access to this possibility of enhancing their life quality and functioning.”
Building on a Legacy of Innovation
This agreement builds on Neuraxpharm’s expanding portfolio of strategic alliances that bridge pharmaceutical and med-tech innovation. It follows the Company’s entry into digital health through the commercialisation agreement with mjn-neuro in 2022 for a wearable device that predicts epileptic seizures, further demonstrating Neuraxpharm’s commitment to realising innovative solutions in CNS care.
